Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

Shaji K Kumar, Angela Dispenzieri, R. Fraser, F. Mingwei, G. Akpek, R. Cornell, M. Kharfan-Dabaja, C. Freytes, S. Hashmi, G. Hildebrandt, L. Holmberg, R. Kyle, H. Lazarus, C. Lee, Joseph R Mikhael, T. Nishihori, J. Tay, S. Usmani, D. Vesole, R. VijB. Wirk, A. Krishnan, C. Gasparetto, T. Mark, Y. Nieto, P. Hari, A. D'Souza

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (<24 months), and to identify factors predicting for early vs late relapses (24-48 months post-AHCT). Over three periods (2001-2004, 2005-2008, 2009-2013), patient characteristics were balanced except for lower proportion of Stage III, higher likelihood of one induction therapy with novel triplets and higher rates of planned post-AHCT maintenance over time. The proportion of patients relapsing early was stable over time at 35-38%. Factors reducing risk of early relapse included lower stage, chemosensitivity, transplant after 2008 and post-AHCT maintenance. Shorter post-relapse OS was associated with early relapse, IgA MM, Karnofsky <90, stage III, >1 line of induction and lack of maintenance. Post-AHCT early relapse remains a poor prognostic factor, even though outcomes have improved over time.

Original languageEnglish (US)
Pages (from-to)986-995
Number of pages10
JournalLeukemia
Volume32
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Cell Transplantation
Multiple Myeloma
Transplants
Recurrence
Drug Combinations
Bone Marrow
Maintenance
Databases
Survival
Research
Population

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. / Kumar, Shaji K; Dispenzieri, Angela; Fraser, R.; Mingwei, F.; Akpek, G.; Cornell, R.; Kharfan-Dabaja, M.; Freytes, C.; Hashmi, S.; Hildebrandt, G.; Holmberg, L.; Kyle, R.; Lazarus, H.; Lee, C.; Mikhael, Joseph R; Nishihori, T.; Tay, J.; Usmani, S.; Vesole, D.; Vij, R.; Wirk, B.; Krishnan, A.; Gasparetto, C.; Mark, T.; Nieto, Y.; Hari, P.; D'Souza, A.

In: Leukemia, Vol. 32, No. 4, 01.04.2018, p. 986-995.

Research output: Contribution to journalArticle

Kumar, SK, Dispenzieri, A, Fraser, R, Mingwei, F, Akpek, G, Cornell, R, Kharfan-Dabaja, M, Freytes, C, Hashmi, S, Hildebrandt, G, Holmberg, L, Kyle, R, Lazarus, H, Lee, C, Mikhael, JR, Nishihori, T, Tay, J, Usmani, S, Vesole, D, Vij, R, Wirk, B, Krishnan, A, Gasparetto, C, Mark, T, Nieto, Y, Hari, P & D'Souza, A 2018, 'Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time', Leukemia, vol. 32, no. 4, pp. 986-995. https://doi.org/10.1038/leu.2017.331
Kumar, Shaji K ; Dispenzieri, Angela ; Fraser, R. ; Mingwei, F. ; Akpek, G. ; Cornell, R. ; Kharfan-Dabaja, M. ; Freytes, C. ; Hashmi, S. ; Hildebrandt, G. ; Holmberg, L. ; Kyle, R. ; Lazarus, H. ; Lee, C. ; Mikhael, Joseph R ; Nishihori, T. ; Tay, J. ; Usmani, S. ; Vesole, D. ; Vij, R. ; Wirk, B. ; Krishnan, A. ; Gasparetto, C. ; Mark, T. ; Nieto, Y. ; Hari, P. ; D'Souza, A. / Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. In: Leukemia. 2018 ; Vol. 32, No. 4. pp. 986-995.
@article{46f65b89afff49d1884f0f5569e576f4,
title = "Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time",
abstract = "Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (<24 months), and to identify factors predicting for early vs late relapses (24-48 months post-AHCT). Over three periods (2001-2004, 2005-2008, 2009-2013), patient characteristics were balanced except for lower proportion of Stage III, higher likelihood of one induction therapy with novel triplets and higher rates of planned post-AHCT maintenance over time. The proportion of patients relapsing early was stable over time at 35-38{\%}. Factors reducing risk of early relapse included lower stage, chemosensitivity, transplant after 2008 and post-AHCT maintenance. Shorter post-relapse OS was associated with early relapse, IgA MM, Karnofsky <90, stage III, >1 line of induction and lack of maintenance. Post-AHCT early relapse remains a poor prognostic factor, even though outcomes have improved over time.",
author = "Kumar, {Shaji K} and Angela Dispenzieri and R. Fraser and F. Mingwei and G. Akpek and R. Cornell and M. Kharfan-Dabaja and C. Freytes and S. Hashmi and G. Hildebrandt and L. Holmberg and R. Kyle and H. Lazarus and C. Lee and Mikhael, {Joseph R} and T. Nishihori and J. Tay and S. Usmani and D. Vesole and R. Vij and B. Wirk and A. Krishnan and C. Gasparetto and T. Mark and Y. Nieto and P. Hari and A. D'Souza",
year = "2018",
month = "4",
day = "1",
doi = "10.1038/leu.2017.331",
language = "English (US)",
volume = "32",
pages = "986--995",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

AU - Kumar, Shaji K

AU - Dispenzieri, Angela

AU - Fraser, R.

AU - Mingwei, F.

AU - Akpek, G.

AU - Cornell, R.

AU - Kharfan-Dabaja, M.

AU - Freytes, C.

AU - Hashmi, S.

AU - Hildebrandt, G.

AU - Holmberg, L.

AU - Kyle, R.

AU - Lazarus, H.

AU - Lee, C.

AU - Mikhael, Joseph R

AU - Nishihori, T.

AU - Tay, J.

AU - Usmani, S.

AU - Vesole, D.

AU - Vij, R.

AU - Wirk, B.

AU - Krishnan, A.

AU - Gasparetto, C.

AU - Mark, T.

AU - Nieto, Y.

AU - Hari, P.

AU - D'Souza, A.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (<24 months), and to identify factors predicting for early vs late relapses (24-48 months post-AHCT). Over three periods (2001-2004, 2005-2008, 2009-2013), patient characteristics were balanced except for lower proportion of Stage III, higher likelihood of one induction therapy with novel triplets and higher rates of planned post-AHCT maintenance over time. The proportion of patients relapsing early was stable over time at 35-38%. Factors reducing risk of early relapse included lower stage, chemosensitivity, transplant after 2008 and post-AHCT maintenance. Shorter post-relapse OS was associated with early relapse, IgA MM, Karnofsky <90, stage III, >1 line of induction and lack of maintenance. Post-AHCT early relapse remains a poor prognostic factor, even though outcomes have improved over time.

AB - Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new drug classes and combinations employed prior to AHCT as well as after post-AHCT relapse may have changed the natural history of MM in this population. We analyzed the Center for International Blood and Marrow Transplant Research database to track overall survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3256) and relapsing early post-AHCT (<24 months), and to identify factors predicting for early vs late relapses (24-48 months post-AHCT). Over three periods (2001-2004, 2005-2008, 2009-2013), patient characteristics were balanced except for lower proportion of Stage III, higher likelihood of one induction therapy with novel triplets and higher rates of planned post-AHCT maintenance over time. The proportion of patients relapsing early was stable over time at 35-38%. Factors reducing risk of early relapse included lower stage, chemosensitivity, transplant after 2008 and post-AHCT maintenance. Shorter post-relapse OS was associated with early relapse, IgA MM, Karnofsky <90, stage III, >1 line of induction and lack of maintenance. Post-AHCT early relapse remains a poor prognostic factor, even though outcomes have improved over time.

UR - http://www.scopus.com/inward/record.url?scp=85044662461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044662461&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.331

DO - 10.1038/leu.2017.331

M3 - Article

C2 - 29263438

AN - SCOPUS:85044662461

VL - 32

SP - 986

EP - 995

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -